Nexstim logo

Nexstim Announces Publication of a Landmark Study Showing Preoperative NBS Mapping Improves Patient Outcome

24 February 2014

Neurosurgeons advocate for increased use of presurgical brain mapping

HELSINKI, Finland- Published in the Oxford Journal Neuro-Oncology, this large-scale study Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions, using Nexstim´s Navigated Brain Stimulation (NBS), was authored by Dr. Sandro Krieg and Professor Bernhard Meyer´s team at the Technical University Munich, Germany.

In the study, 100 patients with lesions located in motor eloquent areas were preoperatively mapped by the Nexstim NBS System which uses navigated TMS. These 100 patients were matched with a control group of 100 patients who had been operated on before the availability of NBS mapping at the Munich hospital.

The group of patients preoperatively mapped by NBS showed a significantly lower rate of residual tumor, as determined by postoperative MRI. On long-term follow-up, 12% of the patients in the NBS group had improved motor function after surgery, compared to only 1% of the patients in the control group. Additionally, using NBS mapping enabled neurosurgeons to use smaller craniotomies.

In their conclusions, the authors strongly advocate navigated TMS to become increasingly used for presurgical mapping of eloquent lesions in the brain, as this large study increases the already existing level of evidence for preoperative motor mapping by navigated TMS. Further, the authors also write in their article that, "Navigated TMS, with comparably easy and cheap availability, represents a remarkable option for non-invasive mappingbecause it is also based on motor evoked potentials via neuronal activation - and therefore has a close relationship to direct cortical stimulation, which is widely used by neurosurgeons. Navigated TMS can be performed in an awake patient and allows surgical planning already at the state of indication."

About Nexstim

Founded in 2000, Finland-based Nexstim Oy is the world leader in image-guided transcranial magnetic stimulation (TMS). The Nexstim NBS System is the first and only FDA-cleared and CE-marked navigated TMS mapping device. Initially being studied as an adjunct to physiotherapy in stroke rehabilitation, Nexstim´s Navigated Brain Therapy (NBT®) System enables personalized, non-drug treatment of brain injury and disease using accurate and repeatable 3D-guidance of the therapeutic electric field. See:

Caution: the NBS System is cleared by the FDA for assessment of the motor and speech cortices for pre-procedural planning. The NBT System is not cleared for marketing in the USA.

Back to Press Releases